Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administration with flying colors. Conducted from August 31 to September 10, 2026, the inspection resulted in zero observations, leading to a clean report from the USFDA and highlighting the facility's commitment to excellence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6w7jzn
via IFTTT